Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer

BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients allowing women to live longer or remain disease-free for longer if the medicines are given before and after surgery as well as in advanced stages of disease.

    Key data being presented include:

    - Herceptin before surgery: Results from the NOAH (NeOAdjuvant Herceptin)
      phase III study showed that women with locally advanced HER2-positive
      breast cancer who started a combination of Herceptin and standard
      chemotherapy prior to surgery had a significantly greater chance of
      living free of their disease (event-free survival) three years after
      initiation of treatment as compared to women who were receiving pre-
      operative chemotherapy alone.

    - Xeloda in early breast cancer: Early data from an independent study in
      Finland and Sweden indicate that the chemotherapy pill Xeloda, which is
      already proven in advanced breast cancer, may also reduce the
      recurrence of early breast cancer and help women live longer. This is
      one of 20 Xeloda abstracts that have been accepted for presentation
      during SABCS.

    - Avastin in advanced breast cancer: First efficacy results from the
      largest ever safety study of Avastin in a real-life setting, which
      involved more than 2,000 patients with locally recurrent or metastatic
      breast cancer, confirm that Avastin can be used with a broad range of
      chemotherapy treatments giving patients a median of almost 10 months
      without their disease getting worse. The results, which are one of 24
      separate Avastin data presentations during SABCS, confirm that Avastin
      based therapy is essential for improving the li
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
(Date:8/22/2014)... 2014  Diplomat, the nation,s largest independent specialty ... winners in the 2014 Innovations in Specialty Pharmacy ... results of the competition were announced in the ... Diplomat was honored as a Top ... program. Through Diplomat University, the company has implemented ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
(Date:8/22/2014)... , Aug. 22, 2014 Research ... "Global and Chinese Particulate Respirators Industry Report 2014" ... Global and Chinese Particulate Respirators Industry Report 2014 is ... of the global particulate respirators industry with a focus ... basic overview of the industry including definitions, classifications, applications ...
Breaking Medicine Technology:Diplomat honored as a Top Innovator by Specialty Pharmacy News 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Global and Chinese Particulate Respirators Industry Report 2014 2
... FALLS CHURCH, Va., May 19, 2011 MinuteClinic, the ... CVS ), and Inova Health System, a leading ... million patients a year, have entered into a clinical ... care services they provide in communities throughout Arlington, Fairfax, ...
... Ampio Pharmaceuticals, Inc. (Nasdaq Capital Market: AMPE) ("Ampio" ... for previously approved drugs and new molecular entities ("NMEs"), ... on the NASDAQ Capital Market under the ticker symbol ... Wingerter, the Company,s CEO, said, "We are extremely excited ...
Cached Medicine Technology:MinuteClinic Forms Strategic Affiliation With Inova Health System in Northern Virginia 2MinuteClinic Forms Strategic Affiliation With Inova Health System in Northern Virginia 3MinuteClinic Forms Strategic Affiliation With Inova Health System in Northern Virginia 4Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market 2
(Date:8/22/2014)... somatic mutation at amino acid 918 in the RET ... cell lung cancer (SCLC) tumors and enforced expression of ... signaling and cell growth. , SCLC is a highly ... lung cancers and is strongly associated with tobacco smoking. ... examined for genomic alterations and targeted therapies are approved ...
(Date:8/22/2014)... Restore My Vision Today , a ... to help people discover how they can get rid ... instead improving their eyesight naturally has caught the attention ... “There’s a reason why the glasses and contacts industry ... people just assume that it’s their only option to ...
(Date:8/22/2014)... Mueller Sports Medicine is excited to ... new product that provides non-drug instant relief for plantar ... you heal. The package includes 7 days of relief, ... – it is not kinesiology tape. It’s made in ... for Plantar Fasciitis is a breakthrough in the ...
(Date:8/22/2014)... News) -- Back-to-school time provides an opportunity for parents ... family schedules, an expert suggests. "Forget New Year,s ... also be the start of a new fitness and ... kinesiology at the University of the Sciences in Philadelphia, ... extracurricular activities likely to build up, "it,s important for ...
(Date:8/22/2014)... CLEVELAND Renal artery stenting to open blockages ... have historically been excluded from modern clinical trials, ... e-published in Catheterization and Cardiovascular Interventions ... Interventions (SCAI). , University Hospitals Case Medical Center,s ... and Professor of Medicine, Case Western Reserve University ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:With Kids in School, Parents Can Work Out 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3
... have developed a Vitamin D pill that could give a ... of prostrate cancer when given along with chemotherapy drugs. ... lived for an average of an extra nine months longer ... edition of BBC News. ,The pill delivers ...
... transplantation—including the psychological and ethical aspects// of the controversial ... of England now endorses moving cautiously forward in performing ... the Jan. 27 issue of Transplantation. ,In ... that facial transplantation should not be attempted until further ...
... new study by researchers at the Harvard School of ... United States //has resulted in a net savings of ... benefits associated with avoided fear and suffering. This first ... vaccination appears as part of a special issue on ...
... gamblers in Britain. A study reveals// that Englishmen prefer to ... fruits. ,On an average, ?800 per year ... Online gambling has also increased the number of gamblers over ... (BMA) has expressed its apprehensions and fears about teenagers getting ...
... pressure in the arteries. High blood pressure (hypertension) //is often ... for years without knowing it. ,A person is ... is around 120/80. Canadians regard blood pressure with systolic reading ... and 89 as high-normal blood pressure. ,Approx. 2.5 ...
... Hospitals, one of the largest eye care hospital networks in ... seven more in the offing. ,The Chennai facility ... prominent ophthalmic surgeon and managing director of Prems' Eye Clinic. ... ,The Vasan Eye Care Group has earmarked a Rs.450 million ...
Cached Medicine News:Health News:Royal College Issues Revised Guidelines for Face Transplantation 2Health News:Royal College Issues Revised Guidelines for Face Transplantation 3Health News:Billions of Dollars Saved in U.S. By Polio Vaccination 2Health News:Slightly High Blood Pressure is Also Hazardous 2
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
... The iCycler iQ real-time PCR detection system ... fits into place directly above the thermal ... excitation/emission wavelengths available, facilitating the greatest array ... part of the iCycler iQ system, the ...
... PRISM 7900HT Sequence Detection System is ... detects and quantitates nucleic acid sequences. ... plate capability make the 7900HT system ... requirements of todays drug discovery process. ...
Chemically Resistant Sealing Mat for 384ch, Square Well Available Sterile...
Medicine Products: